Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207564 · ClinicalTrials.gov registry record
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
A clinical trial of Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 4,500
- Enrollment target
- 2
- Study locations
NCT07207564: Recruiting study of Breast Carcinoma, sponsored by Mayo Clinic.
NCT07207564 is a study of Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 4,500 participants, above the 728-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (518% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207564, a study of Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 4,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to better understand how benign breast diseases might lead to breast cancer, focusing on genetic factors and including a diverse range of participants to improve future diagnosis and treatment.
Primary Outcome
Will examine pathologic features from benign tissue to define features related to breast cancer (BC) risk.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2030-06-30 |
What NCT07207564 shows while recruiting
NCT07207564 is an observational study that tracks outcomes without assigning an intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus, above the 728-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (518% higher).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07207564 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT07207564 about?
NCT07207564 is a clinical study titled "Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk". The purpose of this research is to better understand how benign breast diseases might lead to breast cancer, focusing on genetic factors and including a diverse range of participants to improve future diagnosis and treatment.
What is the current status of trial NCT07207564?
This trial is currently recruiting. The enrollment target is 4,500 participants. The study started on 2025-08-28. Estimated completion is 2030-06-30.
What conditions does trial NCT07207564 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT07207564?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07207564?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207564 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07207564's enrollment target sits among peer trials
4,500 5th of 106 higher than 102 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI